Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: J Immunol. 2016 May 2;196(11):4805–4813. doi: 10.4049/jimmunol.1501982

Figure 1. Down-regulation of NKG2D expression and enhanced spontaneous B cell lymphoma in RAE1ε transgenic mice.

Figure 1

(a) CFSE-labeled OT-I CTL (NKG2D+) were adoptively transferred into a RAE1ε transgenic (RAE1ε Tg) and wild-type mouse. Twenty-four hours later NKG2D expression in the spleens of the recipient mice were analyzed. (b) Tumor mass from RAE1ε transgenic mouse. (c) Tumor mass from wild-type mouse. (d) The number of unique VDJ reads required to reach 5% of total sequencing reads from B cells present in normal spleens of 3 month-old mice or tumor masses from the spleen (circle), lymph node (triangle), or liver (square) of 10–24 month-old RAE1ε (n=7) transgenic mice or >24 month-old wild-type mice (n=2) with a single data point per mouse. (e) NKG2D ligand expression on lymphomas from three WT mice measured by combined staining with antibodies specific for RAE1, H60, and MULT-1. The number shown is the percentage of CD19+ cells with NKG2D ligand staining above control antibody staining. (f) RAE1ε expression on lymphomas from three RAE1ε transgenic mice measured by staining with antibody specific for RAE1ε. The number shown is the percentage of CD19+ cells with RAE1ε staining above control antibody staining. Scale bar: 1mm. *two-tailed Mann-Whitney test. NS: Not statistically different.